Kintor Pharma Announced the Primary Endpoint of Phase II Clinical Study for KX-826's Treatment of Female Androgenetic Alopecia in China Was Met

DJ Kintor Pharma Announced the Primary Endpoint of Phase II Clinical Study for KX-826's Treatment of Female Androgenetic Alopecia in China Was Met EQS Newswire / 02/12/2022 / 10:34 UTC+8 Kintor

Related Keywords

China ,Peking ,Beijing ,Suzhou ,Jiangsu ,Kintor Pharma ,Jianzhong Zhang ,Financial Press ,Kintor Pharmaceutical ,Department Of Dermatology ,University People Hospital ,Kintor Pharmaceutical Limited Pharma ,Pharma Announced ,Primary Endpoint ,Female Androgenetic Alopecia ,China Was Met ,Pharmaceutical Limited ,Peking University People ,Savin Scale ,Youzhi Tong ,Chief Executive Officer ,Kintor Pharma Announced ,Financial Press Release ,Dow Jones Newswires ,Ukintor ,Dharma ,Nnounced ,Primary ,Ndpoint ,Hase ,Linical ,Study ,Treatment ,Female ,Androgenetic ,Alopecia ,